颅底脊索瘤与软骨肉瘤高剂量质子放疗后视力丧失
本研究回顾2007至2018年接受质子放疗的148例颅底脊索瘤或软骨肉瘤患者共283只有功能视力的眼睛,前视路至少接受30GyRBE。中位随访4.1年,5只眼出现功能性失明,5年发生率2.1%(95%CI:0.9-4.9%)。前视路最大剂量低于60GyRBE者无视力丧失事件,超过60GyRBE者粗发生率为3.6%。
要点
- 质子放疗后5年功能性视力丧失发生率为2.1%(95%CI:0.9-4.9%)。
- 前视路最大剂量低于60GyRBE者未观察到视力丧失事件。
- 超过60GyRBE者视力丧失粗发生率为3.6%,事件均发生在60-65GyRBE之间。
核心结论
- 尽管颅底脊索瘤和软骨肉瘤患者接受了高剂量放疗,视力丧失发生率仍较低。
- 前视路最大剂量低于60GyRBE时未发生视力丧失事件。
研究设计与样本
- 回顾性分析2007至2018年接受质子放疗的颅底脊索瘤或软骨肉瘤患者。
- 共纳入148例患者、283只基线有功能视力且前视路0.1cm3至少接受30GyRBE的眼睛。
- 采用Kaplan-Meier法和正常组织并发症概率模型分析剂量与视力丧失风险的关系。
主要发现
- 末次随访时148例患者中110例存活且无疾病进展证据。
- 中位随访4.1年(范围0.5-12.8年),3例患者共5只眼出现功能性失明,其中2例为双侧失明。
- 至失明的中位时间为15.2个月,5年视力丧失发生率为2.1%(95%CI:0.9-4.9%)。
- 单因素分析显示失明与存在多种内科合并症相关(p=0.0040)。
- 前视路最大剂量低于60GyRBE者无事件,超过60GyRBE者粗发生率为3.6%,所有事件发生在60-65GyRBE之间。
关键数值与推荐
- 功能性失明定义为视力20/200或更差。
- 纳入分析的眼睛需前视路0.1cm3至少接受30GyRBE。
- 前视路最大剂量低于60GyRBE者未观察到视力丧失事件。
- 前视路最大剂量超过60GyRBE者视力丧失粗发生率为3.6%,事件均发生于60-65GyRBE。
临床怎么用
- 对于颅底脊索瘤和软骨肉瘤的质子放疗,将前视路最大剂量控制在60GyRBE以下可能降低视力丧失风险。
- 存在多种内科合并症的患者可能需更谨慎评估视力丧失风险。
局限性
- 本研究为回顾性分析,样本来自单中心经验。
- 中位随访时间4.1年,部分患者随访时间较短。
- 视力丧失事件数较少(5只眼),统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & PURPOSE: Dose escalation for skull-based chordoma and chondrosarcoma can put critical adjacent structures at risk, specifically the anterior optic pathway. We report the incidence of vision loss following high-dose conformal proton-based radiotherapy. MATERIALS AND METHODS: We reviewed patients with skull-base chordoma or chondrosarcoma treated with proton-based therapy between 2007 and 2018. We analyzed 148 patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1 cm3 of the anterior optic pathway. Eyes were classified as "functionally blind" if visual acuity was 20/200 or worse. Kaplan-Meier and normal tissue complication probability modeling were used to establish the relationship between radiation dose and risk of functional vision loss. RESULTS: At last follow-up, 110 of 148 patients were alive with no evidence of disease progression. With a median follow-up of 4.1 years (range, 0.5-12.8), 5 eyes in 3 patients developed functional blindness, with 2 patients developing bilateral blindness. Median time to blindness was 15.2 months. The 5-year incidence of vision loss was 2.1% (95% CI: 0.9-4.9%). On univariate analysis, development of blindness was associated with presence of multiple medical comorbidities (p = 0.0040). While there were no events with a maximum dose < 60GyRBE delivered to the anterior optic pathway, the crude rate was 3.6% over 60GyRBE, with all events occurring between 60-65GyRBE. CONCLUSIONS: Despite the high radiotherapy dose delivered to patients with skull-base chordoma and chondrosarcoma, the rate of vision loss is low and no events occurred in those who received a maximum dose under 60GyRBE.
引用
- De Leo AN, Holtzman AL, Ho MW, et al. Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma. Radiother Oncol. 2021. PMID: 33610625. doi:10.1016/j.radonc.2021.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。